

SVT CAPITAL CORP.
800 - 1199 W. Hastings Street
Vancouver, BC V6E 3T5

**SVT ANNOUNCES EXECUTION OF AMALGAMATION AGREEMENT
WITH DELTA 9 BIO-TECH INC.**

May 31, 2017 - Vancouver, BC - SVT Capital Corp. (TSXV:VTC) ("SVT") is pleased to announce that it has entered into a definitive amalgamation agreement dated May 30, 2017 (the "**Amalgamation Agreement**") with Delta 9 Bio-Tech Inc. ("**Delta**"), an arm's length Manitoba-based licensed producer of medical cannabis, pursuant to which SVT has agreed to acquire all of the securities of Delta by way of a three-cornered amalgamation (the "**Transaction**") among SVT, Delta and a wholly-owned subsidiary of SVT formed for the purpose of completing the amalgamation. Pursuant to the terms of the Amalgamation Agreement, the shareholders of Delta will receive one common share of SVT (each, a "**SVT Share**") for each share of Delta held. In connection with the completion of the Transaction (the "**Closing**"), SVT intends to change its name to "Delta 9 Cannabis Inc." or such other name as may be agreed by the parties.

In connection with the execution of the Amalgamation Agreement and further to SVT's news release of April 4, 2017, Delta has completed a brokered bridge loan financing of \$3,000,000 (the "**Bridge Loan**"). The terms of the Bridge Loan include: (a) an interest rate of 10% per annum; (b) a maturity date of one year from the date of the advance of the Bridge Loan (the "**Maturity Date**"); (c) principal and accrued interest payable on the Maturity Date; and (d) all principal plus accrued but unpaid interest thereon being convertible, on the closing of the Amalgamation, into SVT Shares. Canaccord Genuity Corp. acted as agent in respect of the Bridge Loan.

The Transaction will result in the reverse takeover of SVT by Delta (as defined in the policies of the TSX Venture Exchange (the "**TSXV**")). SVT and Delta are parties dealing at arm's length, therefore the Transaction will not be a non-arms' length transaction under the policies of the TSXV. Upon successful completion of the Transaction, it is anticipated that SVT will be listed as a Tier 2 Industrial issuer on the TSXV.

About Delta 9 Bio-Tech Inc.

Delta, a company incorporated under the laws of the Province of Manitoba, founded by the father and son team of Bill and John Arbuthnot in 2012, obtained a production license under the Marihuana for Medical Purposes Regulations in December 2013 followed by its license to distribute medical cannabis in March 2014. Since that time Delta has established itself in its 80,000 square foot production facility in East Winnipeg and grown from 2 employees to 30. Delta is focused on growing small batch, hand trimmed, high quality medical cannabis strains. Delta currently has a rotation of approximately 15 different strains of cannabis that are available to its 1300 medical patients across Canada.

Completion of the Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the Transaction cannot close until the required

shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of SVT should be considered highly speculative.

The TSXV has in no way passed on the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release.

ON BEHALF OF THE BOARD OF DIRECTORS OF SVT CAPITAL CORP.

“Anthony Jackson”

Anthony Jackson
Director

For further information, please contact Anthony Jackson by phone at (604) 782-4119 or by email at ajackson@bridgemark.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Transaction and Delta's future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to the Transaction; terms of the Transaction. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including the risk that the TSXV may not approve the Transaction; that the Transaction may not be completed for any other reason; or that factors may occur which impede or prevent Delta's future development plans. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits SVT will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and SVT disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.